Cargando…
Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)—(Equine) (BAT(®)) in Clinical Study Subjects and Patients: A 15-Year Systematic Safety Review
Botulism is a rare, sometimes fatal paralytic illness caused by botulinum neurotoxins. BAT(®) (Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)—(Equine)) is an equine-derived heptavalent botulinum antitoxin indicated for the treatment of symptomatic botulism in adult and pediatric patients. This...
Autores principales: | Parrera, Geraldine S., Astacio, Hugo, Tunga, Priya, Anderson, Deborah M., Hall, Christine L., Richardson, Jason S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778610/ https://www.ncbi.nlm.nih.gov/pubmed/35050996 http://dx.doi.org/10.3390/toxins14010019 |
Ejemplares similares
-
Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product
por: Anderson, Deborah M., et al.
Publicado: (2019) -
Exposure‐Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product
por: Beliveau, Martin, et al.
Publicado: (2022) -
Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs
por: Barker, Douglas, et al.
Publicado: (2019) -
Results of a Double-Blind, Randomized, Placebo-Controlled Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Anti-Zika Virus Immunoglobulin
por: White, Jane, et al.
Publicado: (2021) -
Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model
por: Emanuel, Andrew, et al.
Publicado: (2019)